The House Energy and Commerce Health Subcommittee today approved legislation that would prohibit Medicare and private health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance. Some health insurance contracts prevent pharmacists from informing patients when the cash price for their prescription costs less than their insurance cost-sharing arrangement unless the individual asks. The subcommittee also approved a bill that would allow the Centers for Medicare & Medicaid Services to provide certain drug rebate information to the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment Advisory Commission to inform their recommendations on drug-related issues.

Headline
The House Energy and Commerce Subcommittee on Health June 25 held a markup session on bills regarding healthcare price transparency, illicit drugs …
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…
Headline
The AHA provided a statement to the House Energy and Commerce Subcommittee on Health today for a hearing titled “Lowering Health Care Costs for All Americans:…
Headline
The House Appropriations Committee June 4 released the fiscal year 2027 appropriations bill for the Departments of Labor, Health and Human Services, Education…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…